JPY 6550.0
(-1.06%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 14.04 Billion | 13.32 Billion | 11.6 Billion | 10.44 Billion | 12.49 Billion |
Cost of Revenue | 12.04 Billion | 11.94 Billion | 11 Billion | 10.6 Billion | 11.55 Billion |
Gross Profit | 1.99 Billion | 1.37 Billion | 600 Million | -154 Million | 938 Million |
Operating Expenses | 80 Million | 82 Million | 98 Million | 185 Million | 302 Million |
Selling, General and Administrative Expenses | 79 Million | 82 Million | 98 Million | 185 Million | 105 Million |
Research and Development Expenses | - | - | - | - | - |
Other Expenses | 1 Million | 147 Million | 424 Million | 497 Million | - |
Cost and Expenses | 12.12 Billion | 12.03 Billion | 11.1 Billion | 10.78 Billion | 11.85 Billion |
Operating Income | 1.91 Billion | 1.29 Billion | 500 Million | -338 Million | 833 Million |
Interest Expense | 44 Million | 46 Million | 51 Million | 54 Million | 50 Million |
Income Tax Expense | 696 Million | 408 Million | 479 Million | 197 Million | 349 Million |
Earnings before Tax | 2.94 Billion | 1.76 Billion | 1.21 Billion | -129 Million | 595 Million |
Net Income | 2.08 Billion | 1.22 Billion | 673 Million | -338 Million | 198 Million |
Earnings Per Share Basic | 1051.33 | 615.67 | 339.05 | -170.11 | 99.60 |
Earnings Per Share Diluted | 1051.33 | 615.67 | 339.05 | -170.11 | 99.60 |
Weighted Average Shares Outstanding | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million |
Weighted Average Shares Outstanding (Diluted) | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million |
Gross Margin | 0.14 | 0.10 | 0.05 | -0.01 | 0.08 |
EBIT Margin | 0.22 | 0.20 | 0.19 | 0.14 | 0.17 |
Profit Margin | 0.15 | 0.09 | 0.06 | -0.03 | 0.02 |
EBITDA | 3.12 Billion | 2.46 Billion | 1.73 Billion | 1.22 Billion | 2.12 Billion |
Earnings Before Tax Margin | 0.14 | 0.10 | 0.04 | -0.03 | 0.07 |
Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Revenue | 3.65 Billion | 14.04 Billion | 3.19 Billion | 4.06 Billion | 3.47 Billion | 3.31 Billion |
Cost of Revenue | 2.91 Billion | 12.04 Billion | 3.13 Billion | 3.29 Billion | 2.86 Billion | 2.74 Billion |
Gross Profit | 747 Million | 1.99 Billion | 61 Million | 766 Million | 601 Million | 565 Million |
Operating Expenses | 14 Million | 79 Million | 17 Million | 23 Million | 17 Million | 22 Million |
Selling, General and Administrative Expenses | 13 Million | - | 17 Million | 23 Million | 17 Million | 22 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 1 Million | 63 Million | 20 Million | 8 Million | 7 Million | 28 Million |
Cost and Expenses | 2.92 Billion | 12.12 Billion | 3.15 Billion | 3.31 Billion | 2.88 Billion | 2.77 Billion |
Operating Income | 733 Million | 1.91 Billion | 44 Million | 742 Million | 585 Million | 542 Million |
Interest Expense | - | 44 Million | 11 Million | 11 Million | 11 Million | 11 Million |
Income Tax Expense | 227 Million | 696 Million | 333 Million | 246 Million | 194 Million | -77 Million |
Earnings before Tax | 742 Million | 2.94 Billion | 990 Million | 740 Million | 604 Million | 613 Million |
Net Income | 460 Million | 2.08 Billion | 653 Million | 444 Million | 357 Million | 635 Million |
Earnings Per Share Basic | 231.47 | - | 328.64 | 223.45 | 179.67 | 319.72 |
Earnings Per Share Diluted | 231.47 | - | 328.64 | 223.45 | 179.67 | 319.72 |
Weighted Average Shares Outstanding | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million |
Weighted Average Shares Outstanding (Diluted) | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million | 1.98 Million |
Gross Margin | 0.20 | 0.14 | 0.02 | 0.19 | 0.17 | 0.17 |
EBIT Margin | 0.28 | - | 0.02 | 0.19 | 0.17 | 0.17 |
Profit Margin | 0.13 | 0.15 | 0.20 | 0.11 | 0.10 | 0.19 |
EBITDA | 1.03 Billion | - | 65 Million | 755 Million | 591 Million | 577 Million |
Earnings Before Tax Margin | 0.20 | 0.14 | 0.01 | 0.18 | 0.17 | 0.16 |
2341
DIGISPICE
CHEMBOND
0842
REEMF
ICIL